News and Trends 4 Jul 2023
Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment
Innovent Biologics, Inc. and IASO Biotechnology have announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first…